Handa Pharmaceuticals Stock Cash And Equivalents
| 6620 Stock | TWD 73.70 3.40 4.41% |
Handa Pharmaceuticals fundamentals help investors to digest information that contributes to Handa Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Handa Stock. The fundamental analysis module provides a way to measure Handa Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Handa Pharmaceuticals stock.
Handa |
Handa Pharmaceuticals Company Cash And Equivalents Analysis
Handa Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Handa Pharmaceuticals Cash And Equivalents | 315.09 M |
Most of Handa Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Handa Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Handa Pharmaceuticals has 315.09 M in Cash And Equivalents. This is 61.62% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all Taiwan stocks is 88.34% higher than that of the company.
Handa Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Handa Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Handa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Handa Pharmaceuticals by comparing valuation metrics of similar companies.Handa Pharmaceuticals is rated below average in cash and equivalents category among its peers.
Handa Fundamentals
| Return On Equity | -41.47 | |||
| Return On Asset | -27.2 | |||
| Current Valuation | 2.86 B | |||
| Shares Outstanding | 115.57 M | |||
| Price To Book | 8.38 X | |||
| Price To Sales | 196.22 X | |||
| Revenue | 28.86 M | |||
| Gross Profit | 68.71 M | |||
| EBITDA | (309.06 M) | |||
| Net Income | (282.1 M) | |||
| Cash And Equivalents | 315.09 M | |||
| Cash Per Share | 2.72 X | |||
| Total Debt | 13.36 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 10.79 X | |||
| Book Value Per Share | 5.85 X | |||
| Cash Flow From Operations | (308.47 M) | |||
| Earnings Per Share | (2.29) X | |||
| Beta | 1.31 | |||
| Market Capitalization | 5.66 B |
About Handa Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Handa Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Handa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Handa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Handa Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Handa Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Handa Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Handa Stock
Moving against Handa Stock
| 0.67 | 2881A | Fubon Financial Holding | PairCorr |
| 0.66 | 2882B | Cathay Financial Holding | PairCorr |
| 0.6 | 2603 | Evergreen Marine Corp | PairCorr |
| 0.57 | 910861 | Digital China Holdings | PairCorr |
| 0.55 | 2820 | China Bills Finance | PairCorr |
The ability to find closely correlated positions to Handa Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Handa Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Handa Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Handa Pharmaceuticals to buy it.
The correlation of Handa Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Handa Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Handa Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Handa Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Handa Stock Analysis
When running Handa Pharmaceuticals' price analysis, check to measure Handa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Handa Pharmaceuticals is operating at the current time. Most of Handa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Handa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Handa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Handa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.